JNJ Halts Development of Depression Drug Over Efficacy Concerns
Portfolio Pulse from
Johnson & Johnson has halted the development of its depression drug, aticaprant, for major depressive disorder due to insufficient efficacy. The company has not completely abandoned the drug but will not pursue it for this specific condition.
March 07, 2025 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Johnson & Johnson has stopped developing its depression drug, aticaprant, for major depressive disorder due to insufficient efficacy. This decision may impact investor sentiment as it reflects challenges in their pharmaceutical pipeline.
The halt in development of aticaprant for major depressive disorder suggests potential setbacks in JNJ's pharmaceutical pipeline, which could negatively affect investor sentiment and short-term stock performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100